1 week Ago By ABMN Staff
Adaptimmune Therapeutics ( NASDAQ:ADAP – Get Free Report ) and Peak Bio ( NASDAQ:PKBO – Get Free Report ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Institutional & Insider Ownership 31.4% of Adaptimmune Therapeutics shares are held by institutional investors.
12.4% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 19.
9% of Peak Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Profitability This table compares Adaptimmune Therapeutics and Peak Bio’s net margins, return on equity and return on assets.
Analyst Ratings Adaptimmune Therapeutics currently has a consensus price target of $3.38, indicating a potential upside of 210.40%.
Given Adaptimmune Therapeutics’ higher possible upside, equities research analysts plainly believe Adaptimmune Therapeutics is more favorable than Peak Bio. Risk & Volatility Adaptimmune Therapeutics has a beta of 2.21, meaning that its stock price is 121% more volatile than the S&P 500.
Comparatively, Peak Bio has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Earnings and Valuation This table compares Adaptimmune Therapeutics and Peak Bio’s gross revenue, earnings per share and valuation.
Peak Bio has lower revenue, but higher earnings than Adaptimmune Therapeutics. Summary Adaptimmune Therapeutics beats Peak Bio on 6 of the 11 factors compared between the two stocks. About Adaptimmune Therapeutics ( Get Free Report ) Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.
It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F.
Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
About Peak Bio ( Get Free Report ) Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome.
It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California. Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
